Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 to \< 85 years of age~* First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior to study enrollment~* At least 6 weeks of stable UE spasticity symptoms (as confirmed by medical history) with a baseline Modified Ashworth Scale (MAS) score of 1+ to 3 (on the 0, 1, 1+, 2, 3, 4 scale), inclusive, in the wrist flexor muscles~* Willing to forgo botulinum toxin, phenol or alcohol injections into the muscles of the limb targeted for the study treatment; intrathecal baclofen; digitalis, and morphine for the subject's duration in the study~* Willing to forgo upper extremity physical and occupational therapy for the duration of the study (lower extremity PT and OT are allowed)~* Willing to maintain current regiment for oral spasticity medication(s) and neurotransmitter medication(s) for the subject's duration in the study~* Cognitive function sufficient to understand the experiments and follow instructions (per interview with appropriate clinician)~Exclusion Criteria:~* Fixed contractures or profound muscle atrophy of the target spastic wrist to be treated~* Change in antispastic oral medication (baclofen, clonidine, benzodiazepine, dantrolene, gabapentin, tizanidine) in the 2 months prior to study enrollment~* Use of digitalis, morphine, or intrathecal pump in the week prior to study enrollment~* Prior botulinum toxin injection(s) into the muscles of the limb targeted for the study treatment within 12 weeks of study enrollment~* Prior phenol or alcohol injections into the muscles of the limb targeted for the study treatment within 6 months of study enrollment~* Prior surgery for spasticity in the target muscle group~* Prior transcranial or trans-spinal direct current stimulation for any reason~* Presence of potential tsDCS risk factors:~  * Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)~ * Lack of sensory perception at the stimulation sites~ * Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders~ * Ferrous metal in the path of the current flow (jewelry must be removed during stimulation)~ * Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months~* Other neurological conditions involving CNS impairment, including Parkinson's Disease, Multiple Sclerosis, and Spinal Cord Injury~* Any medical condition that would prevent the subject from being able to participate in the clinical outcome measures~* Previous participating in a study involving the application of tsDCS~* Pregnancy in women (as determined by pregnancy test in pre-menopausal women)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Active Stimulation (Type: EXPERIMENTAL): Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
- Sham Stimulation (Type: SHAM_COMPARATOR): Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device

Based on this trial design, predict the completion outcome and termination type (if applicable).